HC Wainwright Reiterates “Buy” Rating for Can-Fite BioPharma (NYSE:CANF)

Can-Fite BioPharma (NYSE:CANF)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a $18.00 price target on the stock.

CANF has been the subject of several other reports. EF Hutton Acquisition Co. I raised Can-Fite BioPharma to a “strong-buy” rating in a research note on Wednesday, July 17th. StockNews.com downgraded Can-Fite BioPharma from a “hold” rating to a “sell” rating in a research note on Wednesday, October 30th.

Can-Fite BioPharma Stock Performance

NYSE:CANF opened at $2.07 on Tuesday. Can-Fite BioPharma has a 1 year low of $1.83 and a 1 year high of $4.69. The stock has a market cap of $7.33 million, a P/E ratio of -1.16 and a beta of 1.39. The stock has a 50-day simple moving average of $2.26 and a 200-day simple moving average of $2.52.

Hedge Funds Weigh In On Can-Fite BioPharma

An institutional investor recently raised its position in Can-Fite BioPharma stock. Armistice Capital LLC raised its stake in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 518,853 shares of the company’s stock after buying an additional 136,055 shares during the quarter. Armistice Capital LLC owned about 14.66% of Can-Fite BioPharma worth $1,339,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.